36.54
36.54 (0%)
As of Feb 14, 2025
Apogee Therapeutics, Inc. [APGE]
Source:
Company Overview
Apogee Therapeutics, Inc is a clinical stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (“I&I”) markets, including for the treatment of atopic dermatitis (“AD”), asthma, eosinophilic esophagitis (“EoE”), chronic obstructive pulmonary disease (“COPD”), and other I&I indications.
| Country | United States |
| Headquarters | |
| Phone Number | |
| Industry | |
| CEO | Michael Henderson, M.D. |
| Website |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-216.9 |
| Net Income | $-182.1 |
| Net Cash | $23.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -31.5% |
| Profit as % of Stockholder Equity | -25.4% |
Management Effectiveness
| Return on Equity | -25.4% |
| Return on Assets | -24.2% |
| Turnover Ratio | |
| EBITA | $-216.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $754 |
| Total Liabilities | $37.2 |
| Operating Cash Flow | $-171.2 |
| Investing Cash Flow | $-300.5 |
| Financing Cash Flow | $495.1 |
